Experimental drug halts lung deterioration in IPF
The benefits are seen with the oral preferential PDE4 inhibitor regardless of background antifibrotic use, researchers found
An experimental treatment for idiopathic pulmonary fibrosis can stall the degradation of forced vital capacity in affected patients, new research shows.
Findings from the phase II trial, presented at the American Thoracic Society’s 2022 International Conference last month, suggest the therapy could be effective regardless of background use of antifibrotic agents.
The treatment, dubbed BI 1015550, is an oral preferential inhibitor of phosphodiesterase 4 (PDE4) B subtype developed by Boehringer Ingelheim, which funded the study.
Senior author Dr Toby Maher, from the University of Southern California, Los Angeles, said the results were “very exciting” news for clinicians treating patients with idiopathic pulmonary fibrosis (IPF).
